keyword
MENU ▼
Read by QxMD icon Read
search

Type 3 C Diabetes

keyword
https://www.readbyqxmd.com/read/30547005/higher-hemoglobin-a1c-and-atherogenic-lipoprotein-profiles-in-children-and-adolescents-with-type-2-diabetes-mellitus
#1
James Heath Pelham, Lynae Hanks, Stella Aslibekyan, Shima Dowla, Ambika P Ashraf
Aim: Significant knowledge gaps exist regarding lipoprotein profiles in children with type 2 diabetes mellitus (T2DM). The primary objective was to analyze the type and nature of lipoprotein abnormalities present in children with T2DM and to identify determinants of adverse lipoprotein profiles. The secondary objective was to assess associations with elevated glycated hemoglobin (HbA1C), i.e., <8% vs. ≥8.0% and pediatric dyslipidemias in the setting of T2DM. Methods: This retrospective chart review included children with T2DM who had undergone lipoprotein analysis and were not on lipid lowering medications (n = 93)...
March 2019: Journal of Clinical & Translational Endocrinology
https://www.readbyqxmd.com/read/30545309/metformin-regulates-atrial-sk2-and-sk3-expression-through-inhibiting-the-pkc-erk-signaling-pathway-in-type-2-diabetic-rats
#2
Chang-He Liu, Na Hua, Xi Fu, Yi-Long Pan, Bin Li, Xiao-Dong Li
BACKGROUND: Our previous study showed that metformin regulates the mRNA and protein levels of type 2 small conductance calcium-activated potassium channel (SK2) and type 3 small conductance calcium-activated potassium channels (SK3) in atrial tissue as well as the ion current of atrial myocytes in rats with type 2 diabetes mellitus (T2DM), but the underlying signaling mechanism is unknown. This study aimed to investigate whether metformin regulates atrial SK2 and SK3 protein expression in T2DM rats though the protein kinase C (PKC)/extracellular signal-regulated kinase (ERK) signaling pathway...
December 13, 2018: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/30545066/utility-of-novel-cardiorenal-biomarkers-in-the-prediction-and-early-detection-of-congestive-kidney-injury-following-cardiac-surgery
#3
Jason G E Zelt, Lisa M Mielniczuk, Peter P Liu, Jean-Yves Dupuis, Sharon Chih, Ayub Akbari, Louise Y Sun
Acute Kidney Injury (AKI) in the context of right ventricular failure (RVF) is thought to be largely congestive in nature. This study assessed the utility of biomarkers high sensitivity cardiac troponin T (hs-cTnT), N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP), and neutrophil gelatinase-associated lipocalin (NGAL) for prediction and early detection of congestive AKI (c-AKI) following cardiac surgery. This prospective nested case-control study recruited 350 consecutive patients undergoing elective cardiac surgery requiring cardiopulmonary bypass...
December 12, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/30542397/stem-cell-transplantation-for-the-treatment-of-patients-with-type-1-diabetes-mellitus-a-meta-analysis
#4
Jiadi Gan, Yingjin Wang, Xiaodong Zhou
The efficacy of stem cell (SC) transplantation in patients with type 1 diabetes mellitus (T1DM) has remained to be fully elucidated. In the present study, a systematic review and meta-analysis was performed to determine the clinical outcomes. Electronic databases, including PubMed, MEDLINE, WanFang and the Cochrane Library were screened for relevant studies published until January 13, 2018. The references of retrieved papers, systematic reviews and trial registries were manually screened for additional papers...
December 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/30541217/-effects-of-berberine-on-the-serum-cystatin-c-levels-and-urine-albumin-creatine-ratio-in-patients-with-type-2-diabetes-mellitus
#5
Z Y Li, B Liu, X J Zhuang, Y D Shen, H R Tian, Y Ji, L X Li, F Liu
Objective: To investigate the effects of berberine on urine albumin/creatine ratio (UACR) and serum cystatin C (Cys C) in patients with type 2 diabetes mellitus (T2DM). Methods: A total of 114 T2DM inpatients or outpatients, including 46 males and 68 females aged (55±14) years between January 2015 and January 2016 were randomly divided into two groups: the control group ( n =57) only with hypoglycemic agents, and the intervention group ( n =57) with berberine (0.4 g, 3 times a day) on the basis of treatment from the control group...
December 11, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/30539648/unravelling-reno-protective-effects-of-sglt2-inhibition-in-human-proximal-tubular-cells
#6
Markus Pirklbauer, Ramona Schupart, Lisa Christina Fuchs, Petra Staudinger, Ulrike Corazza, Sebastian Sallaberger, Johannes Leierer, Gert Mayer, Herbert Schramek
Large clinical trials demonstrated that SGLT2 inhibitors (SGLT2i) slow the progression of kidney function decline in type 2 diabetes. As the underlying molecular mechanisms are largely unknown, we studied the effects of SGLT2i on gene expression in two human proximal tubular (PT) cell lines under normoglycemic conditions, utilizing two SGLT2i, namely empagliflocin and canagliflocin. Genome-wide expression analysis did not reveal substantial differences between these two SGLT2i. Microarray hybridization analysis identified 94 genes that were both upregulated by TGF-ß1 and downregulated by either of the two SGLT2i in HK-2 and RPTEC/TERT1 cells...
December 12, 2018: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/30539523/a-review-of-the-safety-and-adverse-event-profile-of-the-fixed-ratio-combination-of-insulin-glargine-and-lixisenatide
#7
REVIEW
Juan P Frias, Terry Dex, Michelle Roberts, Allen Kaplan
INTRODUCTION: iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (100 units/mL) and lixisenatide (33 μg/mL). This review evaluates the overall safety and adverse event (AE) profile of iGlarLixi in patients with type 2 diabetes. METHODS: We collated patient-level data from the phase 2 LixiLan proof-of-concept trial and the phase 3 LixiLan-L (insulin-experienced patients) and LixiLan-O (insulin-naïve patients) trials to evaluate AEs associated with iGlarLixi...
December 11, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/30537305/dietary-protein-affects-both-the-dose-and-pattern-of-insulin-delivery-required-to-achieve-postprandial-euglycaemia-in-type-1-diabetes-a-randomized-trial
#8
M Evans, C E M Smart, N Paramalingam, G Smith, T W Jones, B R King, E A Davis
AIM: To quantify the insulin requirement for a high-protein meal compared with a low-protein meal, controlling for carbohydrate and fat content. METHODS: In this crossover study, young people with Type 1 diabetes were randomized to consume a high- (60 g) or low-protein meal (5 g), each containing 30 g carbohydrate and 8 g fat. A variation of the insulin clamp technique was used to determine the insulin requirements to maintain euglycaemia for the following 5 h. RESULTS: A total of 11 participants (mean ± sd age 16...
December 7, 2018: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/30537226/how-representative-are-the-patients-included-in-the-cv-outcome-trials-with-sglt2-inhibitors-of-a-general-type-2-diabetes-population-a-large-european-observational-study
#9
K I Birkeland, J Bodegard, A Norhammar, J G Kuiper, Elena Georgiado, W L Beekman-Hendriks, M Thuresson, Marc Pignot, R M C Herings, A Kooy
AIMS: Enrollment criteria vary substantially between the cardiovascular outcome trials (CVOTs) of sodium-glucose cotransporter-2 inhibitors (SGLT-2is), impacting how representative a trial population is to the general type 2 diabetes (T2D) population. The aim was to evaluate the representativeness of four SGLT-2i CVOTs to a general T2D population. METHODS: T2D patients were included from Germany, the Netherlands, Norway, and Sweden. Given the available data per country, key inclusion and exclusion criteria were defined by diagnoses, procedures, and drug treatments to facilitate comparability between countries...
December 9, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/30537180/a-randomized-multicentre-trial-evaluating-the-efficacy-and-safety-of-fast-acting-insulin-aspart-in-continuous-subcutaneous-insulin-infusion-in-adults-with-type-1-diabetes-onset-5
#10
David C Klonoff, Mark L Evans, Wendy Lane, Hans-Peter Kempe, Eric Renard, J Hans DeVries, Tina Graungaard, Agon Hyseni, Theis Gondolf, Tadej Battelino
AIMS: To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart [FA]) vs insulin aspart (IAsp) in continuous subcutaneous insulin infusion (CSII) in participants with type 1 diabetes. MATERIALS AND METHODS: Double-blind, treat-to-target, randomized, 16-week trial investigating CSII treatment with FA (n = 236) or IAsp (n = 236). All available information regardless of treatment discontinuation was used for the evaluation of effect. RESULTS: FA was non-inferior to IAsp regarding the change from baseline in HbA1c (primary endpoint)...
December 9, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/30536789/addition-of-glp-1ra-therapy-to-insulin-in-c-peptide-positive-patients-with-type-1-diabetes
#11
Nitesh D Kuhadiya, Ben Prohaska, Husam Ghanim, Paresh Dandona
OBJECTIVE: We tested the hypothesis that addition of GLP-1 receptor agonists (GLP-1RA) to insulin in c-peptide positive patients with T1D will result in a reduction in hemoglobin A1C (HbA1c) with reduced insulin requirements and a rise in c-peptide concentrations. METHODS: This is a retrospective analysis of 11 normal weight patients with T1D consecutively treated with GLP-1RA in addition to insulin. Paired t tests were used to compare the changes in HbA1c, insulin doses, body weight, body mass index, and C-peptide concentrations prior to and 12 ± 1 week after GLP-1RA therapy...
December 9, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/30536572/dysglycemia-among-youth-with-type-1-diabetes-and-suboptimal-glycemic-control-in-the-flexible-lifestyle-empowering-change-flex-trial
#12
Anna R Kahkoska, Jamie Crandell, Kimberly A Driscoll, Jessica C Kichler, Michael Seid, Elizabeth J Mayer-Davis, David M Maahs
OBJECTIVE: To examine the prevalence and correlates of non-severe hypoglycemia in adolescents with type 1 diabetes and suboptimal glycemic control, an understudied topic in this group. METHODS: Seven days of blinded continuous glucose monitor data were analyzed in 233 adolescents at baseline of the Flexible Lifestyle Empowering Change (FLEX) trial (13-16 years, type 1 diabetes duration >1 year, and hemoglobin A1c (HbA1c) 8-13% [64-119 mmol]). Incidence of clinical hypoglycemia (54-69 mg/dL) and clinically serious hypoglycemia (<54 mg/dL) was defined as number of episodes ≥15 min...
December 10, 2018: Pediatric Diabetes
https://www.readbyqxmd.com/read/30536565/platelet-storage-properties-are-associated-with-donor-age-in-vitro-quality-of-platelets-from-young-donors-and-older-donors-with-and-without-type-2-diabetes
#13
Ido J Bontekoe, Pieter F van der Meer, Arthur J Verhoeven, Dirk de Korte
BACKGROUND AND OBJECTIVES: Previously it has been shown that platelet (PLT) storage performance is consistent by donor. Differences involved metabolic activity, which might be caused by mitochondrial (dys)function, associated with age and age-related diseases like Type 2 diabetes (T2D). We aimed to test PLTs from young donors in comparison with PLTs from older donors with or without diagnosis for T2D. MATERIALS AND METHODS: Fifteen whole blood donors <30 year were selected, and single-donor platelet concentrates (sPC) were prepared from buffy coats (BC) and plasma...
December 10, 2018: Vox Sanguinis
https://www.readbyqxmd.com/read/30535871/sitagliptin-vs-pioglitazone-as-add-on-treatments-in-patients-with-uncontrolled-type-2-diabetes-on-the-maximal-dose-of-metformin-plus-sulfonylurea
#14
P Khaloo, S Asadi Komeleh, H Alemi, M A Mansournia, A Mohammadi, A Yadegar, M Afarideh, S Esteghamati, M Nakhjavani, A Esteghamati
AIMS: To compare the efficacy of sitagliptin versus pioglitazone as add-on drugs in patients with poorly controlled diabetes with metformin and sulfonylureas. METHODS: This is a randomized, open-label, parallel assignment clinical trial. Patients who had inadequate glycemic control [7% (53 mmol/mol) ≤ A1C < 11% (97 mmol/mol)] despite a minimum 6-month period of active treatment with metformin 2000 mg/day plus gliclazide 240 mg/day were enrolled in the study...
December 10, 2018: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/30534894/-finding-of-a-new-mutation-in-a-chilean-family-with-monogenic-diabetes-report-of-one-case
#15
Marcos Estica R, Daniela Seelenfreund H, Pilar Durruty A, Gloria Briones B
We report a 21 years old woman, without offspring, with diabetes mellitus diagnosed at 17 years of age, without ketosis or weight loss. Her body mass index was 18 kg/m2. Her C peptide was normal (2.3 ng/ml) and diabetes mellitus type 1 autoantibodies were negative. A monogenic diabetes Maturity Onset Diabetes of the Young (MODY) was proposed. Her family study disclosed a diabetic father and a brother with altered fasting glucose levels. The University of Exeter score for MODY yielded a 75.5% probability of MODY2...
July 2018: Revista Médica de Chile
https://www.readbyqxmd.com/read/30530850/proinsulin-secretion-is-a-persistent-feature-of-type-1-diabetes
#16
Emily K Sims, Henry T Bahnson, Julius Nyalwidhe, Leena Haataja, Asa K Davis, Cate Speake, Linda A DiMeglio, Janice Blum, Margaret A Morris, Raghavendra G Mirmira, Jerry Nadler, Teresa L Mastracci, Santica Marcovina, Wei-Jun Qian, Lian Yi, Adam C Swensen, Michele Yip-Schneider, C Max Schmidt, Robert V Considine, Peter Arvan, Carla J Greenbaum, Carmella Evans-Molina
OBJECTIVE: Abnormally elevated proinsulin secretion has been reported in type 2 and early type 1 diabetes when significant C-peptide is present. We questioned whether individuals with longstanding type 1 diabetes and low or absent C-peptide secretory capacity retained the ability to make proinsulin. RESEARCH DESIGN AND METHODS: C-peptide and proinsulin were measured in fasting and stimulated sera from 319 subjects with long-standing type 1 diabetes (≥3 years) and 12 control subjects without diabetes...
December 10, 2018: Diabetes Care
https://www.readbyqxmd.com/read/30530527/association-of-triglyceride-to-hdl-cholesterol-ratio-with-cardiometabolic-outcomes
#17
May Yang, Joseph Rigdon, Sandra A Tsai
Electronic medical records (EMRs) offer a potential opportunity to identify patients at high risk for cardiometabolic disease, which encompasses type 2 diabetes and cardiovascular disease (CVD). The objective of this retrospective cohort study is to use information gathered from EMR to investigate the association between triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C) and cardiometabolic outcomes in a general population of subjects over 50 years of age during a follow-up period of 8-9 years...
December 9, 2018: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/30529824/a-novel-analytical-approach-towards-in-vitro-bile-acid-binding-studies-to-colesevelam-hydrochloride-tablets-an-ultra-high-performance-liquid-chromatography-tandem-mass-spectrometric-method
#18
Sunny Raina, Ashish Mungantiwar, Supriya Halde, Nancy Pandita
Colesevelam hydrochloride is a bile acid sequestrant used as a low density lipoprotein (LDL) reducing agent in hyperlipidemia with an additional advantage to improve glycemic control in type 2 diabetes patients. The objective of the study was to develop and validate a liquid chromatography tandem mass spectroscopic method for the simultaneous in-vitro estimation of bile acid salts of Glycocholic acid (GC), Glycochenodeoxycholic acid (GCDC) and Taurodeoxycholic acid (TDC) and its application in performing in-vitro binding study with Colesevelam Hydrochloride tablets...
November 30, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/30529784/the-impact-of-type-2-diabetes-on-bone-metabolism-and-growth-after-spinal-fusion
#19
Neil Bhamb, Linda E A Kanim, Ruben C Maldonado, Trevor J Nelson, Khosrowdad Salehi, Juliane D Glaeser, Melodie F Metzger
BACKGROUND CONTEXT: Some clinical reports suggest diabetes may have a negative effect on spinal fusion outcomes, although no conclusive experimental research has been conducted to investigate the causality, impact, and inherent risks of this growing patient population. PURPOSE: To analyze the hypothesis that type II diabetes (T2DM) inhibits the formation of a solid bony union after spinal fusion surgery by altering the local microenvironment at the fusion site through a reduction in growth factors critical for bone formation...
December 7, 2018: Spine Journal: Official Journal of the North American Spine Society
https://www.readbyqxmd.com/read/30529097/association-of-atp-binding-cassette-transporter-1-abca-1-gene-polymorphism-with-type-2-diabetes-mellitus-t2dm-in-bangladeshi-population
#20
Mehedi Hasan, Bayejid Hosen, Mostafijur Rahman, M Zakir Hossain Howlader, Yearul Kabir
AIMS: ATP-binding cassette transporter A1 (ABCA1) gene polymorphism has been reported as one of the genetic risk factors for T2DM in various populations with conflicting results. The aim of this study is to investigate the association of ABCA1 C69T polymorphism and lipid profile with T2DM in Bangladeshi population. MATERIALS AND METHODS: A total of 102 T2DM subjects and 98 healthy controls were recruited and their genotypes for ABCA1 gene polymorphisms were determined based on the PCR-RFLP technique...
December 7, 2018: Gene
keyword
keyword
159777
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"